Program
darolutamide
Also written as “Darolutamide”, “Darolutamide (Nubeqa, BAY1841788)” and “Darolutamide (BAY1841788, Nubeqa)”.
Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Bulbo-Spinal Atrophy, X-Linked · Neoplasms · Neoplasm Metastasis, led by 2 companies.
Drug pageDarolutamide: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 164 open or running | phase 4since Apr 21, 2022 | Jul 22, 2014 | Jul 30, 2027phase 3 · NCT05794906 |
| Orion Corporation, Orion Pharma | 40 open or running | phase 2since Mar 7, 2011 | Mar 7, 2011 | none ahead |
Also a collaborator on its studies: Keenova Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Orion Corporation, Orion Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Mar 7, 2011First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT01317641 · 136 enrolled · United States, Czech Republic, Estonia and more
- Sep 1, 2011Phase 2 study in Prostatic NeoplasmsNCT01429064 · 76 enrolled · United States, Czech Republic, Estonia and more
- Feb 4, 2013Phase 1 study in Prostatic NeoplasmsNCT01784757 · 30 enrolled · Latvia
- Mar 24, 2015Phase 1 study in HealthyNCT02418650 · 12 enrolled · United Kingdom
- Jun 9, 2016Named darolutamideINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ODM-201
TargetBeta
“A formulation containing an androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 4 Orion Corporation, Orion Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02418650Healthy · United Kingdom | 1 | Completed | May 2015 | 12 |
| NCT01784757Prostatic Neoplasms · Latvia | 1 | Completed | Aug 2013 | 30 |
| NCT01429064Prostatic Neoplasms · United States, Czech Republic, Estonia and more | 2 | Completed | Nov 2015 | 76 |
| NCT01317641Prostatic Neoplasms · United States, Czech Republic, Estonia and more | 2 | Completed | Jul 2013 | 136 |
How it is read
Names in the registry
- “Darolutamide”, 6 entries
- “Darolutamide (Nubeqa, BAY1841788)”, 5 entries
- “Darolutamide (BAY1841788, Nubeqa)”, 2 entries
- “BAY1841788 (ODM-201)”, 2 entries
- “ODM-201”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 15 studies
- Prostatic Neoplasms, Castration-Resistant, 2 studies
- Bulbo-Spinal Atrophy, X-Linked, 1 study
- Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.